Pfizer announces acceptance of regulatory submissions by u.s. fda and european medicines agency for sutent® (sunitinib) for adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma after surgery

2nd June 2017 Uncategorised 0

Pfizer

More: Pfizer announces acceptance of regulatory submissions by u.s. fda and european medicines agency for sutent® (sunitinib) for adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma after surgery
Source: MDlinx